David Charles Baker
DirectorMr. David Charles Baker, also known as Dave, served as a Chief Scientific Officer at Fable Therapeutics, Inc. and serves as its Member of Metabolic Scientific Advisory Board. Mr. Baker served as the President and Consultant of DB Biopharma Consulting LLC, since April 2023. He served as Independent Director of Devonian Health Group Inc. since May 12, 2023 until March 27, 2026 and served as its Non-executive Chairman from December 04, 2023 until June 2024. He has served as a member of the Board at GRI Bio, Inc. from January 15, 2019 until August 23, 2019 and serves as Director since February 12, 2021. He is President and Chief Executive Officer at Vallon Pharmaceuticals, Inc. since January 15, 2019 and is its Director since February 12, 2021. Mr. Baker was a Member of the Board at Vallon Pharmaceuticals, Inc. until August 23, 2019 and was its Consultant since January 15, 2018. He was Chief Commercial Officer of Arcturus Therapeutics Ltd. (formerly known as Alcobra, Ltd.) since October 19, 2017. Mr. Baker served as an Interim Chief Executive Officer at Alcobra Ltd. from June 1, 2017 to October 19, 2017. Mr. Baker joined Alcobra after serving 10 years at Shire Pharmaceuticals as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit. In this role he led the commercial assessment of neuroscience licensing opportunities, managed commercial efforts on pipeline CNS products and led the long term strategic planning process. Previously, he served as Global General Manager for Shire Vyvanse® where he led a global cross-functional team responsible for the development, manufacture and commercialization of Vyvanse and Adderall XR(R). He served as Chief Commercial Officer at Alcobra Ltd. (now known as Arcturus) from January 2014 to June 1, 2017. He led the launch of Vyvanse in 2007, oversaw the launch of the adult indication for Vyvanse in 2008 and led global expansion efforts to take Shire's ADHD portfolio beyond North America including successful establishment of a partnership in Japan and launches in Canada and Brazil. Prior to that, Mr. Baker served as Vice President of Marketing for all of Shire's ADHD products. Under his leadership, Adderall XR became the number one selling ADHD brand in the US, Daytrana(R) was launched as the first ADHD patch and late stage development and pre-launch commercial efforts for Intuniv(R) were completed. From 1990 to 2004, Mr. Baker worked at Merck & Co., where he held positions of increasing responsibility in marketing, sales, market research and business development. Mr. Baker's therapeutic expertise includes osteoporosis, migraine and hyperlipidemia. He serves on the board of directors of Benchworks, Inc. Mr. Baker graduated Magna Cum Laude with a bachelor's degree in Economics and Computer Science from Duke University. He earned a Master of Business Administration in Marketing from Duke's Fuqua School of Business.
Positions
- Company NameGRI Bio, Inc.Stock CodeGRIPositionDirectorColleagues
- WMW. Marc HertzCo-Founder, CEO, President & Director
- DLDavid L. SzekeresIndependent Chairman of the Board
- VKVipin Kumar ChaturvediCo-Founder & Chief Scientific Officer
- LMLeanne M. KellyCFO & Corporate Secretary
- AAAlbert AgroCo-Founder & Chief Medical Officer
- RRRoelof RongenIndependent Director
- CVCamilla V. SimpsonIndependent Director
